Skip to content

Exploring the application of remimazolam besylate in general anesthesia induction and maintenance for laparoscopic surgery

Exploring the application of remimazolam besylate in general anesthesia induction and maintenance for laparoscopic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119912
Enrollment
Unknown
Registered
2026-03-05
Start date
2026-03-05
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for laparoscopic surgery

Interventions

Group B:Continuous infusion of remimazolam besylate at 4.2 µg/ml intravenously. Both groups waited until the patient lost consciousness and eyelash reflex, with BIS 60 three minutes after induction, t
Group C:The anesthesia induction begins with the continuous infusion of the analgesic drug remifentanil at 3ug/ml and the sedative drug propofol at 1-2mg/kg. Wait until the patient loses consciousness

Sponsors

Shouguang Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective laparoscopic cholecystectomy or laparoscopic hernia repair at Shouguang Traditional Chinese Medicine Hospital. 2. Aged between 20 and 65 years. 3. American Society of Anesthesiologists (ASA) Physical Status Classification of I-III (i.e., from healthy to mild systemic disease with good functional compensation). 4. Willing to participate and able to sign this informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to the study drugs (remimazolam besylate, propofol, alfentanil, sufentanil, etc.) or related components. 2. Suffering from severe mental illness, consciousness disorder, or Alzheimer's disease (dementia). 3. Having severe hematologic diseases, cardiovascular or cerebrovascular diseases (such as unstable angina, severe arrhythmia, uncontrolled hypertension), or severe valvular heart disease affecting hemodynamics. 4. Long-term abuse of alcohol or drugs. 5. Anticipated difficult tracheal intubation (Mallampati class III-IV). 6. Severe hepatic or renal insufficiency. 7. Any other condition deemed by the investigator to make the subject unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
The success rate of anesthesia induction.;

Secondary

MeasureTime frame
Hemodynamic stability during the induction period.;Time to awakening after drug withdrawal, extubation time;;

Countries

China

Contacts

Public ContactSong Zhiyong

Shouguang Traditional Chinese Medicine Hospital

t5262337@126.com+86 536 503 8125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026